Introduction
Eccrine porocarcinoma, a malignant sweat gland tumor, represents only 0.005%-3.5% of epithelial cutaneous neoplasms.1 In 1963, the first reported case was attributed to Pinkus et al,2 who coined it as “epidermotropic eccrine carcinoma”. In 1969, Mishma et al introduced the term “eccrine porocarcinoma”.3 This tumor may arise from a preexisting benign poroma or may also develop as a verrucous or nodular, ulcerative growth. The most common sites are lower extremities (50%), trunk (24%), head and neck (18%), upper extremities (2%) and hands (3%).4 Microscopically the tumor frequently presents with both intraepidermal and dermal invasion and is capable of forming satellite lesions and lymphatic involvement. Porocarcinoma may present as a dome-shaped papule, plaque or nodule growing over weeks to months. The exact incidence of porocacrcinoma is unknown but appears to be rising. Management involves removal of the tumor, usually using wide local excision or MMS. Prognosis is poor in EPC with recurrence rate of 20% after surgery which can be both local recurrences as well as regional lymph node metastases. Distant metastasis occurs in 12% of cases. The sites for distant and visceral metastases are lung, retroperitoneum, femur, breast, liver, mediastinum, urinary bladder, peritoneum, and ovary in that order. The mortality rate is > 65% when regional nodes are involved.5